Clinical Trial Detail

NCT ID NCT02599714
Title Study of AZD2014 and Palbociclib in Patients With Estrogen Receptor Positive (ER+) Metastatic Breast Cancer (PASTOR)
Recruitment Active, not recruiting
Gender female
Phase Phase Ib/II
Variant Requirements yes
Sponsors AstraZeneca
Indications

Her2-receptor negative breast cancer

Therapies

Fulvestrant + Palbociclib

Vistusertib

Age Groups: adult

Additional content available in CKB BOOST